Sentrimed

Sentrimed is an emerging, private biotech company founded in 2015, advancing a novel oncology platform centered on 'contact normalization'—a cellular communication process that enables normal cells to inhibit and destroy tumor cells. Led by a team with deep oncology experience, including founder and CSO Dr. Gary Goldberg, the company is developing a pipeline of oral, tumor-agnostic therapies and has compounds in human trials. While still pre-revenue, Sentrimed's approach targets a broad range of cancers and is supported by NIH grants, positioning it in a competitive but high-potential segment of the oncology market.

Proprietary platform focused on 'contact normalization,' a cell-to-cell communication process that enables normal cells to inhibit tumor growth and migration. The platform targets novel validated pathways like podoplanin (PDPN) inhibition to develop tumor-agnostic, oral therapies.

Sentrimed competes in the broad and highly competitive oncology therapeutics market, facing competition from large pharmaceutical companies, biotechs developing targeted therapies, and immuno-oncology players. Its differentiation lies in its novel contact normalization mechanism and tumor-agnostic, oral approach, but it must demonstrate clinical efficacy to secure a position.